A Study of Soticlestat Tablets in Healthy Adults

The drug being tested in this study is called soticlestat (TAK-935). The study will assess the bioequivalence, effect of food and tablet crushing, safety and tolerability following single oral dose of 3 different soticlestat oral tablet formulations in healthy participants. The study will enroll approximately 96 participants. This study will be conducted in two parts (Part A and Part B) having 6 treatment sequences each. Participants will be randomly assigned (by chance, like flipping a coin) to one of the study parts as per treatment sequence: * Part A, Sequence 1: Treatment A + Treatment B + Treatment C * Part A, Sequence 2: Treatment A + Treatment C + Treatment B * Part A, Sequence 3: Treatment B + Treatment A + Treatment C * Part A, Sequence 4: Treatment B + Treatment C + Treatment A * Part A, Sequence 5: Treatment C + Treatment A + Treatment B * Part A, Sequence 6: Treatment C + Treatment B + Treatment A * Part B, Sequence 1: Treatment D + Treatment E + Treatment F * Part B, Sequence 2: Treatment D + Treatment F + Treatment E * Part B, Sequence 3: Treatment E + Treatment D + Treatment F * Part B, Sequence 4: Treatment E + Treatment F + Treatment D * Part B, Sequence 5: Treatment F + Treatment D + Treatment E * Part B, Sequence 6: Treatment F + Treatment E + Treatment D This single center trial will be conducted in the United States. The overall duration of the study is approximately 51 days. Participants will be followed up for 14 days after the last dose of study drug for a follow-up assessment.